Found 5 matching trials
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) PHASE2 This is a Phase 2, multicenter, open-label study to provide continued suppl...
Show More Status
Active Not Recruiting
Location
Uab Comprehensive Cancer Center
Learn More & Join Trial
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) PHASE1 Open-label, dose-escalation study in subjects with previously treated B-cel...
Show More Location
University of Alabama At Birmingham Comprehensive Cancer Center
Learn More & Join Trial
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies PHASE1 This was a study of INCB052793 given to patients with advanced malignancies...
Show More Location
Multiple Locations
Learn More & Join Trial
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors PHASE1 This is an open-label, Phase 1b, platform study in subjects with advanced o...
Show More Location
Multiple Locations
Learn More & Join Trial
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors PHASE1 This is an open-label, multicenter, Phase 1b platform study in subjects wit...
Show More Location
University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Learn More & Join Trial